Caplin Point Laboratories Share Price Falls Over 3% After Q2 FY27 Earnings Results: Total Income Up 17.5% YoY

On November 12, 2026, Caplin Point Laboratories Limited's Board of Directors approved the unaudited consolidated financial results for the quarter and half year ended September 30, 2026, as per the exchange filings.  

For Q2 FY27 total income rose 17.5% year on year to ₹663.13 crore, while net profit grew 13.8% to ₹182.35 crore. 

Caplin Point Laboratories Q2 and H1 FY27 Financial Performance 

For the quarter ended September 30, 2026, Caplin Point posted total income of ₹663.13 crore, up from ₹564.41 crore a year ago and 3.0% higher than ₹643.91 crore in the June 2026 quarter.  

Consolidated revenue from operations grew 17.9% year on year to ₹629.84 crore, EBITDA reached ₹256.51 crore at a 38.7% margin, and net profit rose to ₹182.35 crore from ₹160.23 crore a year earlier and 1.8% from ₹179.09 crore in Q1 FY27.  

For H1 FY27, total income climbed 19.1% year on year to ₹1,307.04 crore from ₹1,097.77 crore, EBITDA reached ₹503.54 crore, and net profit rose 16.2% to ₹361.44 crore from ₹310.99 crore across Rest of the World (₹976.19 crore) and USA (₹264.01 crore) segments.  

For FY26, total income stood at ₹2,302.73 crore and net profit was ₹649.73 crore. 

Balance Sheet, Operations and Capital Expenditure 

As of September 30, 2026, consolidated total assets stood at ₹4,374.93 crore with ₹3,953.26 crore in total equity, while free cash reserves reached ₹1,534 crore and liquid assets totalled ₹2,967 crore.  

Consolidated H1 FY27 operating cash flow was ₹205.25 crore and free cash flow was ₹70 crore after ₹135 crore capital expenditure.  

In emerging markets, Caplin won $53,00,000 in Central American tenders and $50,00,000 in Chilean tenders, gained acceptance for 6 products across 3 pharmacy chains in Chile, and secured 4 new approvals alongside 33 existing approvals in Mexico.  

Caplin Steriles Limited launched 40 US products, while Caplin Steriles USA Inc. served over 5,600 customers with daily average sales rising from $32,936 to $61,330.  

Caplin also allocated over ₹1,000 crore in internal accrual capital expenditure across completed facilities and ongoing projects scheduled for CY27, Q1 FY28, and Q2 FY28. 

Read More: Cochin Shipyard Share Price Falls Over 6% Post Q2 FY27 Earnings Results: Total Income Up 6.9% YoY! 

Caplin Point Laboratories Share Price Performance  

As of November 12, 2026, at 1:39 PM, Caplin Point Laboratories share price on NSE was trading at ₹2,423.50, down by 3.84% from the previous closing price. 

Conclusion 

Caplin Point Laboratories reported Q2 FY27 total income of ₹663.13 crore, up 17.5%, and net profit of ₹182.35 crore, up 13.8%, while H1 FY27 total income reached ₹1,307.04 crore, net profit stood at ₹361.44 crore, and liquid assets totalled ₹2,967 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.